The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Update: Category 2 Removals Explained FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP 1s BioSpace Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed Compounded "semaglutide" is not FDA approved semaglutide.com